Publication

IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services [Maryland, January 2024] – IBT Bioservices, a renowned figure in

IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the

CARB-X global partnership headed toward developing an innovative vaccine against potentially deadly Staphylococcus aureus bacteria that could be a “game

IBT Vaccines, a wholly owned subsidiary of Integrated Biotherapeutics Inc., announces it has received $3.9 million to advance the development of

4 November 2019   INTEGRATED BIOTHERAPEUTICS TO PRESENT ON NOVEL VACCINES FOR MRSA AT WORLD ANTI-MICROBIAL CONGRESS 2019   Integrated

CATEGORIES

RECENT POSTS

IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services

CARB-X global partnership headed toward developing an innovative vaccine against

IBT CEO Dr. M. Javad Aman will discuss the development

SUBSCRIBE HERE!

Subscribe to the IBT Bioservices Tech Talk list and receive periodic updates on industry news and IBT Bioservices products and services.